Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Zevra Therapeutics (ZVRA) over the last 9 years, with Q2 2025 value amounting to $148.3 million.

  • Zevra Therapeutics' Other Operating Expenses changed N/A to $148.3 million in Q2 2025 from the same period last year, while for Sep 2025 it was $148.3 million, marking a year-over-year increase of 43134.89%. This contributed to the annual value of -$78.9 million for FY2023, which is 220.33% up from last year.
  • As of Q2 2025, Zevra Therapeutics' Other Operating Expenses stood at $148.3 million.
  • Zevra Therapeutics' 5-year Other Operating Expenses high stood at $148.3 million for Q2 2025, and its period low was -$25.9 million during Q3 2023.
  • Moreover, its 5-year median value for Other Operating Expenses was $91000.0 (2022), whereas its average is $8.9 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 305000.0% in 2021, then tumbled by 2856153.85% in 2023.
  • Zevra Therapeutics' Other Operating Expenses (Quarter) stood at $59000.0 in 2021, then skyrocketed by 55.93% to $92000.0 in 2022, then tumbled by 26308.7% to -$24.1 million in 2023, then grew by 14.35% to -$20.7 million in 2024, then skyrocketed by 818.21% to $148.3 million in 2025.
  • Its Other Operating Expenses stands at $148.3 million for Q2 2025, versus -$20.7 million for Q1 2024 and -$24.1 million for Q4 2023.